Annexon (ANNX) Competitors $2.52 -0.12 (-4.55%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$2.66 +0.14 (+5.36%) As of 07:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANNX vs. SYRE, NRIX, NAGE, ARDX, AVDL, PHVS, CRMD, AKBA, OCS, and LENZShould you be buying Annexon stock or one of its competitors? The main competitors of Annexon include Spyre Therapeutics (SYRE), Nurix Therapeutics (NRIX), Niagen Bioscience (NAGE), Ardelyx (ARDX), Avadel Pharmaceuticals (AVDL), Pharvaris (PHVS), CorMedix (CRMD), Akebia Therapeutics (AKBA), Oculis (OCS), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry. Annexon vs. Its Competitors Spyre Therapeutics Nurix Therapeutics Niagen Bioscience Ardelyx Avadel Pharmaceuticals Pharvaris CorMedix Akebia Therapeutics Oculis LENZ Therapeutics Annexon (NASDAQ:ANNX) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, community ranking, dividends, earnings, profitability, valuation and institutional ownership. Does the MarketBeat Community believe in ANNX or SYRE? Annexon received 35 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 78.08% of users gave Annexon an outperform vote. CompanyUnderperformOutperformAnnexonOutperform Votes5778.08% Underperform Votes1621.92% Spyre TherapeuticsOutperform Votes22100.00% Underperform VotesNo Votes Do insiders and institutionals hold more shares of ANNX or SYRE? 80.4% of Spyre Therapeutics shares are held by institutional investors. 11.9% of Annexon shares are held by company insiders. Comparatively, 15.4% of Spyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is ANNX or SYRE more profitable? Annexon's return on equity of -38.99% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AnnexonN/A -38.99% -33.90% Spyre Therapeutics N/A -210.01%-44.40% Which has better valuation & earnings, ANNX or SYRE? Annexon has higher earnings, but lower revenue than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnexonN/AN/A-$134.24M-$1.18-2.14Spyre Therapeutics$890K1,219.07-$338.79M-$3.77-4.77 Do analysts rate ANNX or SYRE? Annexon presently has a consensus price target of $12.50, indicating a potential upside of 396.03%. Spyre Therapeutics has a consensus price target of $53.40, indicating a potential upside of 196.67%. Given Annexon's higher possible upside, equities research analysts plainly believe Annexon is more favorable than Spyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annexon 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Which has more volatility & risk, ANNX or SYRE? Annexon has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.72, suggesting that its share price is 172% more volatile than the S&P 500. Does the media prefer ANNX or SYRE? In the previous week, Annexon had 1 more articles in the media than Spyre Therapeutics. MarketBeat recorded 5 mentions for Annexon and 4 mentions for Spyre Therapeutics. Annexon's average media sentiment score of 1.44 beat Spyre Therapeutics' score of 1.12 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAnnexon beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks. Get Annexon News Delivered to You Automatically Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANNX vs. The Competition Export to ExcelMetricAnnexonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$276.48M$6.85B$5.57B$8.63BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-2.408.7827.1320.06Price / SalesN/A255.64412.28157.10Price / CashN/A65.8538.2534.64Price / Book0.796.557.064.70Net Income-$134.24M$143.93M$3.23B$247.88M7 Day Performance-1.18%3.84%2.86%2.63%1 Month Performance42.37%11.20%9.05%6.36%1 Year Performance-58.28%4.18%31.39%14.05% Annexon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANNXAnnexon2.4745 of 5 stars$2.52-4.5%$12.50+396.0%-53.8%$276.48MN/A-2.4060Positive NewsAnalyst RevisionSYRESpyre Therapeutics2.4074 of 5 stars$15.40+0.8%$53.40+246.8%-52.6%$928.25M$890K-2.0673Positive NewsNRIXNurix Therapeutics2.1499 of 5 stars$12.14+14.2%$30.44+150.8%-21.8%$925.51M$56.42M-4.20300High Trading VolumeNAGENiagen Bioscience1.5046 of 5 stars$11.73+8.4%$13.00+10.8%N/A$923.97M$107.93M69.00120News CoverageAnalyst ForecastHigh Trading VolumeARDXArdelyx3.9691 of 5 stars$3.85+4.9%$10.39+169.8%-44.2%$921.13M$361.71M-24.0690Insider TradeAnalyst RevisionAVDLAvadel Pharmaceuticals2.1754 of 5 stars$9.49+4.2%$19.43+104.7%-35.2%$918.05M$194.45M-12.0170Positive NewsAnalyst RevisionPHVSPharvaris1.4579 of 5 stars$16.49-0.7%$40.67+146.6%+7.4%$862.26MN/A-5.8930Trending NewsAnalyst ForecastAnalyst RevisionGap UpCRMDCorMedix0.5757 of 5 stars$12.70+4.6%$15.00+18.1%+188.9%$861.38M$82.55M-15.6830Positive NewsAKBAAkebia Therapeutics4.4693 of 5 stars$3.25+7.3%$6.63+103.8%+221.6%$853.57M$184.91M-14.13430High Trading VolumeOCSOculis1.7955 of 5 stars$19.22-1.2%$31.50+63.9%+64.7%$839.18M$980K-9.962Positive NewsShort Interest ↑Analyst RevisionLENZLENZ Therapeutics1.6954 of 5 stars$29.16-0.1%$46.60+59.8%+58.1%$820.74MN/A-16.47110Positive News Related Companies and Tools Related Companies SYRE Competitors NRIX Competitors NAGE Competitors ARDX Competitors AVDL Competitors PHVS Competitors CRMD Competitors AKBA Competitors OCS Competitors LENZ Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANNX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annexon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
